|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||175.71 - 181.22|
|52 Week Range||124.73 - 182.47|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||11.38|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||200.80|
A spokeswoman for Takeda declined to comment. Takeda’s takeover of Shire -- the largest announced global deal of 2018 -- vaulted it into the ranks of the 10 biggest drugmakers by sales, but also more than doubled the Japanese firm’s borrowing level. Takeda’s management has stressed the importance of maintaining its credit ratings at investment grade, and hybrid debt can help achieve that as ratings firms may view the bonds as having an equity component depending on their structure.
The company is working with Bank of America Corp. to gauge potential buyer interest in emerging-market assets it acquired through its 2011 purchase of Swiss rival Nycomed, according to the people, who asked not to be identified because the information is private. The medicines, which include over-the-counter and prescription drugs, could fetch about $3 billion, the people said. Shares of Takeda rose as much as 2.5 percent in early Tokyo trading Tuesday and were up 1 percent at 9:59 a.m. Deliberations are at an early stage, and there’s no certainty they will result in a transaction, according to the people.
Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.
Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.
January 11, 2019 – Shire plc (“Shire”) and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire (“SAIIDAC”), announced today that they have notified the New York Stock Exchange (the “NYSE”) of their intention to apply for the voluntary delisting of SAIIDAC’s outstanding 1.900% Senior Notes due 2019, 2.400% Senior Notes due 2021, 2.875% Senior Notes due 2023 and 3.200% Senior Notes due 2026 (collectively, the “Notes”), which are guaranteed by Shire.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE.
Director/PDMR Shareholding January 8, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by persons discharging managerial responsibilities.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
On May 8, 2018, Shire plc (“Shire”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the “Acquisition”). On January 3, 2019, Shire announced that the Royal Court of Jersey had sanctioned the Scheme at the Court Sanction Hearing held on January 3, 2019.
The joint company is expected to bring in more than $31 billion in annual revenue from a portfolio of cancer, neurological, gastrointestinal and rare disease drugs.
Holding(s) in Company January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.
(Bloomberg Opinion) -- During the past 16 months, Celgene Inc. has gone from biotech darling to pariah after a series of research fumbles. On Thursday, Bristol-Myers Squibb Co. — which has had its own share-price stumbles after cancer setbacks — rode to Celgene’s rescue and possibly its own with a $74 billion dollar cash-and-stock deal.
Shire plc (“Shire”) is pleased to announce that the Royal Court of Jersey has today sanctioned the scheme of arrangement pursuant to Article 125 of the Companies (Jersey) Law 1991 (as amended) (the “Scheme”) by which the recommended cash and share offer made by Takeda Pharmaceutical Company Limited (“Takeda”) for the entire issued and to be issued share capital of Shire (the “Acquisition”) is being implemented. There has been no change to the expected timetable of principal events for the Acquisition set out on pages 1 to 3 of the scheme document published on November 12, 2018 in relation to the Acquisition (the “Scheme Document”). Applications have been made for the suspension of trading in Shire Shares on the London Stock Exchange's main market for listed securities and the listing of Shire Shares on the premium listing segment of the Official List of the UK Listing Authority and such suspensions are expected to take effect from 7.30 a.m. (London time) on January 7, 2019.
Total Voting Rights January 2, 2019 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”).
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.